Switch to
More onapp

Gujarat Themis Biosyn Ltd

GUJTHEM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,105 cr, stock is ranked 1,032
Moderate RiskStock is 2.85x as volatile as Nifty
742.0019.85 (-2.61%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,105 cr, stock is ranked 1,032
Moderate RiskStock is 2.85x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
25.34
PB RatioPB Ratio
10.70
Dividend YieldDiv. Yield
1.45%
Sector PESector PE
34.15
Sector PBSector PB
4.18
Sector Div YldSctr Div Yld
0.92%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The company makes bulk drugs. It's R&D division focuses on developing fermentation cultures. The Company's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.

Financial TrendFinancial statements 

201920202021202243.2686.8293.83118.906.4123.6730.1843.62
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Company Update 
Announced OnDec 1, 2022

GUJARAT THEMIS BIOSYN LTD. - 506879 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Download

GUJARAT THEMIS BIOSYN LTD. - 506879 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Download

Cash Dividend 
Ex. DateDec 1, 2022

Interim • Div/Share: ₹ 4.4

Cash Dividend 
Ex. DateAug 29, 2022

Final • Div/Share: ₹ 4

See all events